Table of Contents

Clinical Studies

• Open Access

  First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules – A Case Report

  MOHAMAD W. SALKINI, XUQING YANG, FAYYAZ HAIDER HASHMI, STANLEY J. KANDZARI, THOMAS HOGAN, CHAD MORLEY, DAVID ZEKAN, ZACHARY WERNER, DORIAN J. WILLIAMS, YI GUO, THOMAS LEWIS MATTHEW, MICHAEL SPANGLER and JING JIE YU

  Anticancer Research March 2022, 42 (3) 1339-1344; DOI: https://doi.org/10.21873/anticanres.15602
• Open Access

  Indocyanine Green Labeling of Tumors in the Liver Recurring After Radiofrequency Ablation Enables Complete Resection by Fluorescence-guided Surgery

  YOSHIHIKO TASHIRO, TAKESHI AOKI, TAKAHITO HIRAI, TOMOTAKE KOIZUMI, TOMOKAZU KUSANO, KAZUHIRO MATSUDA, KOSUKE YAMADA, KOJI NOGAKI, TOMOKI HAKOZAKI, YUSUKE WADA, HIDEKI SHIBATA, KODAI TOMIOKA, TATSUYA YAMAZAKI, KAZUHIKO SAITO, AKIRA FUJIMORI, YUTA ENAMI and ROBERT M. HOFFMAN

  Anticancer Research March 2022, 42 (3) 1345-1350; DOI: https://doi.org/10.21873/anticanres.15603
• Open Access

  Rarely Described Renal Malignancies Associated With Venous Tumor Thrombus

  MARIA C. VELASQUEZ, ALI MOUZANNAR, SANJAYA SWAIN and GAETANO CIANCIO

  Anticancer Research March 2022, 42 (3) 1351-1358; DOI: https://doi.org/10.21873/anticanres.15604
• You have access

  Risk of Second Primary Malignancies After External Beam Radiotherapy for Thyroid Cancer

  MICHAEL C. JIN, Z. JASON QIAN and UCHECHUKWU C. MEGWALU

  Anticancer Research March 2022, 42 (3) 1359-1365; DOI: https://doi.org/10.21873/anticanres.15605
• Open Access

  Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer

  THOMAS HECKING, THORE THIESLER, JANINA HALBE, LUCIA OTTEN, FLORIAN RECKER, HEIDRUN GEVENSLEBEN, TIM MÜLLER, CYNTHIA SCHILLER, EVA K. EGGER, ROLF FIMMERS, MATTHIAS B. STOPE, GLEN KRISTIANSEN and ALEXANDER MUSTEA

  Anticancer Research March 2022, 42 (3) 1367-1376; DOI: https://doi.org/10.21873/anticanres.15606
• You have access

  Long-term Outcome of Acral Ewing Sarcoma

  KATHERINE E. MALLETT, MARK J. HEIDENREICH, ZERAHIAH M. JOSEPH, CHLOE COPPER, PETER S. ROSE, STEVEN L. MORAN and MATTHEW T. HOUDEK

  Anticancer Research March 2022, 42 (3) 1377-1380; DOI: https://doi.org/10.21873/anticanres.15607
• Open Access

  Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin

  JAMES J. SALLER, MINTALLAH HAIDER, SAMEER AL-DIFFALHA and DOMENICO COPPOLA

  Anticancer Research March 2022, 42 (3) 1381-1396; DOI: https://doi.org/10.21873/anticanres.15608
• You have access

  Improving Survival Prognostication in Patients With Metastatic Cancer Through Clinical Judgment

  JOHNNY KAO, AMANDA ZUCKER, MICHELLE URSO, PAWEL KARWOWSKI, NEHA JAIN, SHOURYA JAIN, GIOVANNA BUSTAMANTE, DEBORAH LUGO and LUANN ROWLAND

  Anticancer Research March 2022, 42 (3) 1397-1401; DOI: https://doi.org/10.21873/anticanres.15609
• You have access

  Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma

  SHOHEI KOMATSU, YOSHIHIKO YANO, YOSHIMI FUJISHIMA, JUN ISHIDA, MASAHIRO KIDO, KAORI KURAMITSU, ATSUSHI YAMAMOTO, TADAHIRO GOTO, HIROAKI YANAGIMOTO, HIROCHIKA TOYAMA, YOSHIHIDE UEDA, YUZO KODAMA and TAKUMI FUKUMOTO

  Anticancer Research March 2022, 42 (3) 1403-1412; DOI: https://doi.org/10.21873/anticanres.15610
• You have access

  Platelet to Lymphocyte Ratio Correlates With Carcinoma Progression in Pancreatic Intra Epithelial Neoplasia

  DORIS WAGNER, JOHANNES HAYBAECK, VALERIE WIENERROITHER, TARIK BAJRIC, ANDREA TOMBERGER, PETER SCHEMMER, HANS-JÖRG MISCHINGER and PETER KORNPRAT

  Anticancer Research March 2022, 42 (3) 1413-1419; DOI: https://doi.org/10.21873/anticanres.15611
• You have access

  Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs)

  SHINICHIRO KASHIWAGI, YUKA ASANO, KOJI TAKADA, WATARU GOTO, TAMAMI MORISAKI, MASATSUNE SHIBUTANI, HIROAKI TANAKA, KOSEI HIRAKAWA and MASAICHI OHIRA

  Anticancer Research March 2022, 42 (3) 1421-1431; DOI: https://doi.org/10.21873/anticanres.15612
• You have access

  Efficacy of a Flat Low Dose of Nivolumab in Advanced Cancer: A Retrospective Case Series

  SOFIE JORIS, CHRISTEL FONTAINE, LORE DECOSTER, JACQUES VANDERAUWERA, KRIS THIELEMANS, WIM WAELPUT and JACQUES DE-GRÈVE

  Anticancer Research March 2022, 42 (3) 1433-1437; DOI: https://doi.org/10.21873/anticanres.15613
• Open Access

  Carbon-ion Radiotherapy for Inoperable Head and Neck Bone and Soft-tissue Sarcoma: Prospective Observational Study

  ATSUSHI MUSHA, NOBUTERU KUBO, HIDEMASA KAWAMURA, NAOKO OKANO, HIRO SATO, KOHEI OKADA, NAOTO OSU, HIKARU YUMISAKI, AKIKO ADACHI, YUKIHIRO TAKAYASU, MASATO SHINO, OSAMU NIKKUNI, SHOTA IDA, KATSUYUKI SHIRAI, JUN-ICHI SAITOH, SATOSHI YOKOO, KAZUAKI CHIKAMATSU, TATSUYA OHNO and WORKING GROUP ON HEAD AND NECK TUMORS

  Anticancer Research March 2022, 42 (3) 1439-1446; DOI: https://doi.org/10.21873/anticanres.15614
• Open Access

  sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma

  VIVIAN BARAK, INA KALICKMAN and JACOB PE’ER

  Anticancer Research March 2022, 42 (3) 1447-1453; DOI: https://doi.org/10.21873/anticanres.15615
• You have access

  Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes

  STELLA CLAUSEN, MARKUS FALK, FLORIAN OESTERLING, ANDRÉ FEHR, ANDREAS STANG, WERNER BOECKER, STEFAN GESK, STEFANIE SCHATZ, GÖRAN STENMAN, KATHARINA TIEMANN, THOMAS LOENING and REINHARD E. FRIEDRICH

  Anticancer Research March 2022, 42 (3) 1455-1463; DOI: https://doi.org/10.21873/anticanres.15616
• Open Access

  Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice

  ATSUSHI MIZOKAMI, KOSHIRO NISHIMOTO, HIDEYASU MATSUYAMA, TOMOHIKO ICHIKAWA, SATORU TAKAHASHI, HIROAKI SHIINA, KATSUYOSHI HASHINE, YUTAKA SUGIYAMA, MANABU KAMIYAMA, HIDEKI ENOKIDA and KENICHI NAKAJIMA

  Anticancer Research March 2022, 42 (3) 1465-1475; DOI: https://doi.org/10.21873/anticanres.15617
• You have access

  Independent External Validation of the METSSS Model Predicting Survival After Palliative Radiotherapy

  CARSTEN NIEDER, BARD MANNSÅKER and ROSALBA YOBUTA

  Anticancer Research March 2022, 42 (3) 1477-1480; DOI: https://doi.org/10.21873/anticanres.15618
• You have access

  Thyroid Follicular Cell-derived Carcinomas in a Background of Multiple Adenomatous Nodules Leading to a Diagnosis of PTEN Hamartoma Tumor Syndrome in an Adult Patient With a Novel RECQL4 Mutation

  ALEX LIU, PAULA M. BORGES, YOU SHER TAY, LESTER D.R. THOMPSON, MAX X. KONG and JINPING LAI

  Anticancer Research March 2022, 42 (3) 1481-1485; DOI: https://doi.org/10.21873/anticanres.15619
• You have access

  Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?

  CHIARA CICCARESE, ROBERTO IACOVELLI, SEBASTIANO BUTI, FRANCESCA PRIMI, SERENA ASTORE, FRANCESCO MASSARI, MIRIAM GRAZIA FERRARA, GIUSEPPE PALERMO, NAZARIO FOSCHI, VALERIO IACOVELLI, ERNESTO ROSSI, GIOVANNI SCHINZARI, PIERLUIGI BOVE, PIERFRANCESCO BASSI, EMILIO BRIA and GIAMPAOLO TORTORA

  Anticancer Research March 2022, 42 (3) 1487-1493; DOI: https://doi.org/10.21873/anticanres.15620
• You have access

  Should 68Ga-PSMA PET/CT Replace CT and Bone Scan in Clinical Staging of High-risk Prostate Cancer?

  PIETRO PEPE and MICHELE PENNISI

  Anticancer Research March 2022, 42 (3) 1495-1498; DOI: https://doi.org/10.21873/anticanres.15621
• Open Access

  Neutrophil-to-Lymphocyte Ratio as a Predictor of Postoperative Recurrence and Prognosis in Oesophageal Squamous Cell Carcinoma

  MANATO OHSAWA, YOICHI HAMAI, MANABU EMI, YUTA IBUKI, TOMOAKI KUROKAWA, TORU YOSHIKAWA, RYOSUKE HIROHATA, NAO KITASAKI and MORIHITO OKADA

  Anticancer Research March 2022, 42 (3) 1499-1507; DOI: https://doi.org/10.21873/anticanres.15622
• You have access

  Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas

  SARI JAAMAA, RIIKKA NEVALA, KIRAN JAGARLAMUDI, ERKKI TUKIAINEN, CARL BLOMQVIST and MIKA SAMPO

  Anticancer Research March 2022, 42 (3) 1509-1515; DOI: https://doi.org/10.21873/anticanres.15623
• Open Access

  Non-invasive Screening of Autoimmune Atrophic Gastritis in Asymptomatic Subjects by Serological Biomarker Test (GastroPanel^®)

  NATALIA BAKULINA, SERGEY TIKHONOV, VLADIMIR MALKOV, SERGEY VOROBYEV, ILYA BELYAKOV, NATALIYA PESHKOVA, ELENA BELKO and KARI SYRJÄNEN

  Anticancer Research March 2022, 42 (3) 1517-1526; DOI: https://doi.org/10.21873/anticanres.15624
• You have access

  Effect of Neoadjuvant Chemotherapy in Patients With Locally Advanced Rectal Cancer: A Multicenter Propensity Score-matched Analysis

  HIROKI KATAYAMA, TETSURO TOMINAGA, TAKASHI NONAKA, MASATO ARAKI, YORIHISA SUMIDA, HIROAKI TAKESHITA, HIDETOSHI FUKUOKA, KAZUO TO, KENJI TANAKA, TERUMITSU SAWAI and TAKESHI NAGAYASU

  Anticancer Research March 2022, 42 (3) 1527-1533; DOI: https://doi.org/10.21873/anticanres.15625
• You have access

  Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab

  HIDEAKI SUEMATSU, KAZUKI KANO, TAKANOBU YAMADA, ITARU HASHIMOTO, HAYATO WATANABE, KOSUKE TAKAHASHI, MAMORU WATANABE, KEI HAYASHI, YOSHIHIRO KANETA, MITSUHIRO FURUTA, YASUHIRO INOKUCHI, NOZOMU MACHIDA, TORU AOYAMA, HIROSHI TAMAGAWA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, TAKASHI OGATA and TAKASHI OSHIMA

  Anticancer Research March 2022, 42 (3) 1535-1540; DOI: https://doi.org/10.21873/anticanres.15626
• You have access

  Prognostic Predictors After Surgical Intervention for Stage IV Gastric Cancer

  SATOSHI SUZUKI, NAOKI URAKAWA, HIROSHI HASEGAWA, SHINGO KANAJI, KIMIHIRO YAMASHITA, TAKERU MATSUDA, TARO OSHIKIRI and YOSHIHIRO KAKEJI

  Anticancer Research March 2022, 42 (3) 1541-1546; DOI: https://doi.org/10.21873/anticanres.15627
• You have access

  PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer

  TATSUYA ITO, ISAKU OKAMOTO, KUNIHIKO TOKASHIKI, HIROKI SATO, TAKURO OKADA, GAI YAMASHITA, TOSHITAKA NAGAO, HIDEAKI HIRAI, NATSUKI SAIGUSA and KIYOAKI TSUKAHARA

  Anticancer Research March 2022, 42 (3) 1547-1554; DOI: https://doi.org/10.21873/anticanres.15628
• You have access

  Management of Soft-tissue Tumors With a Size of 2-5 cm, Including Malignancy

  YOSHIHIRO ARAKI, NORIO YAMAMOTO, TORU MAEDA, HIROAKI KIMURA, TAKASHI OTA, SHINGO SHIMOZAKI, TAKASHI KATO, DAISUKE INOUE, TAKASHI HIGUCHI, KENSAKU ABE, YUTA TANIGUCHI and HIROYUKI TSUCHIYA

  Anticancer Research March 2022, 42 (3) 1555-1562; DOI: https://doi.org/10.21873/anticanres.15629
• You have access

  Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer

  MARTIN SVATON, MARIE DROSSLEROVA, ONDREJ FISCHER, MILOSLAV MAREL, MICHAL HRNCIARIK, ONDREJ VENCLICEK, PETR ZUNA, MICHAL SVOBODA, JIRI BLAZEK, MONIKA BRATOVA, ANDREA MULLEROVA, BOHUSLAVA VANKOVA and DANIEL KREJCI

  Anticancer Research March 2022, 42 (3) 1563-1569; DOI: https://doi.org/10.21873/anticanres.15630
• You have access

  Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study

  NOBUKI FURUBAYASHI, FUTOSHI MOROKUMA, TOSHIHISA TOMODA, YOSHIFUMI HORI, TAKAHITO NEGISHI, AKIHIRO MIURA, HIROKI KOMORI, KENTARO KUROIWA and MOTONOBU NAKAMURA

  Anticancer Research March 2022, 42 (3) 1571-1577; DOI: https://doi.org/10.21873/anticanres.15631
• You have access

  Clinical Features and Treatment Outcomes of Pseudoaneurysm Following Pancreatic Resection

  YASURO FUTAGAWA, SHINJI ONDA, SHUICHI FUJIOKA, TERUYUKI USUBA, YUKIO NAKABAYASHI, TAKEYUKI MISAWA, TOMOYOSHI OKAMOTO and TORU IKEGAMI

  Anticancer Research March 2022, 42 (3) 1579-1588; DOI: https://doi.org/10.21873/anticanres.15632
• You have access

  The Gut Microbiome as a Biomarker of Cancer Progression Among Female Never-smokers With Lung Adenocarcinoma

  TAKEHIRO OTOSHI, TATSUYA NAGANO, JONGUK PARK, KOJI HOSOMI, TOMOYA YAMASHITA, MOTOKO TACHIHARA, TOKIKO TABATA, REINA SEKIYA, YUGO TANAKA, KAZUYUKI KOBAYASHI, KENJI MIZUGUCHI, TOMOO ITOH, YOSHIMASA MANIWA, JUN KUNISAWA and YOSHIHIRO NISHIMURA

  Anticancer Research March 2022, 42 (3) 1589-1598; DOI: https://doi.org/10.21873/anticanres.15633
• You have access

  Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab

  YUKA MASUDA, YOSHIKAZU KANANAZAWA, KUNIHIKO MATSUNO, DAISUKE KAKINUMA, NOBUYUKI SAKURAZAWA, FUMIHIKO ANDO, NOBUTOSHI HAGIWARA, TSUTOMU NOMURA, SHUNJI KATO, TOSHIRO YOSHIYUKI and HIOSHI YOSHIDA

  Anticancer Research March 2022, 42 (3) 1599-1605; DOI: https://doi.org/10.21873/anticanres.15634
• You have access

  Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma

  TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, YUSUKE AIHARA, KENJI HANYU, YUKIOMI KUSHIHASHI, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, YUKI HARADA, KAHO MOMIYAMA, TAKU YAMASHITA, GO OMURA, HIDEAKI TAKAHASHI, NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA

  Anticancer Research March 2022, 42 (3) 1607-1613; DOI: https://doi.org/10.21873/anticanres.15635
• You have access

  First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea

  MI-HYUN KIM, CHANG MIN CHOI, SUNG YONG LEE, CHEOL KYU PARK, YOON SOO CHANG, KYE YOUNG LEE, SEUNG JOON KIM, SEI HOON YANG, JEONG SEON RYU, JEONG EUN LEE, SHIN YUP LEE, CHAN KWON PARK, SANG HOON LEE, SEUNG HUN JANG, SEONG HOON YOON and TAE WON JANG

  Anticancer Research March 2022, 42 (3) 1615-1622; DOI: https://doi.org/10.21873/anticanres.15636
• You have access

  Is Preoperative Spirometry Necessary for Gastrointestinal Cancer Surgery?

  MASATO MITSUDA, HIROKI SHIMIZU, YOSHIAKI KURIU, TAKESHI KUBOTA, TOMOHIRO ARITA, TAKUMA OHASHI, JUN KIUCHI, YUSUKE YAMAMOTO, HIROTAKA KONISHI, RYO MORIMURA, ATSUSHI SHIOZAKI, HISASHI IKOMA, HITOSHI FUJIWARA, KAZUMA OKAMOTO and EIGO OTSUJI

  Anticancer Research March 2022, 42 (3) 1623-1628; DOI: https://doi.org/10.21873/anticanres.15637
• You have access

  Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma

  IKKO TOMISAKI, MIRII HARADA, AKINORI MINATO, YUJIRO NAGATA, RIEKO KIMURO, KATSUYOSHI HIGASHIJIMA, KENICHI HARADA and NAOHIRO FUJIMOTO

  Anticancer Research March 2022, 42 (3) 1629-1634; DOI: https://doi.org/10.21873/anticanres.15638
• You have access

  Primary Malignant Osseous Neoplasms in the Hand

  SHOTA IKE, MASATAKE MATSUOKA, TOMOHIRO ONODERA, ISAO YOKOTA, KOJI IWASAKI, RYOSUKE HISHIMURA, YUKI SUZUKI, EIJI KONDO and NORIMASA IWASAKI

  Anticancer Research March 2022, 42 (3) 1635-1640; DOI: https://doi.org/10.21873/anticanres.15639
• You have access

  Awake Craniotomy for Subcortical Brain Metastasis Beneath the Speech Center: A Technical Case Report

  RYOSUKE MATSUDA, MASASHI KOTSUGI, KENTA NAKASE, TAKAYUKI MORIMOTO, FUMIHIKO NISHIMURA, ICHIRO NAKAGAWA and HIROYUKI NAKASE

  Anticancer Research March 2022, 42 (3) 1641-1644; DOI: https://doi.org/10.21873/anticanres.15640
• You have access

  Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation

  KAZUKI MATSUMURA, KENSUKE YAMAMURA, HIDEAKI MIYAMOTO, YOSHIHIRO HARA, ERI ODA, SHINICHI AKAHOSHI, KENICHIRO YOSHIDA, HIDEAKI YUKI, TOSHIHIKO MOTOHARA, KATSUNORI SAKAMOTO, YOSHIHIRO KOMOHARA and TORU BEPPU

  Anticancer Research March 2022, 42 (3) 1645-1651; DOI: https://doi.org/10.21873/anticanres.15641
• You have access

  A Case of Salvage Maxillectomy for Recurrent Oral Cancer After Boron Neutron Capture Therapy During the COVID-19 Pandemic

  HIDENORI SUZUKI, MAI YOKOI, SUMITAKA HAGIWARA, EIICHI SASAKI, YOSHIAKI KOBAYASHI, SHO IWAKI, DAISUKE NISHIKAWA, SHINTARO BEPPU, HOSHINO TERADA, MICHI SAWABE and NOBUHIRO HANAI

  Anticancer Research March 2022, 42 (3) 1653-1657; DOI: https://doi.org/10.21873/anticanres.15642